#None #Biologics #Ailux #Lloyd S. Miller

Ailux Strengthens Leadership with Appointment of Dr. Lloyd S. Miller

Ailux, an innovative biotech company specializing in AI-driven biologics, has announced the appointment of Dr. Lloyd S. Miller, M.D., Ph.D., as the new Chief Medical Officer (CMO). This strategic move is aimed at accelerating the company's development of its groundbreaking biologic therapies and enhancing its research capabilities. The announcement was made on October 13, 2026, amidst ongoing efforts to bring its first AI-native programs into clinical trials by 2027.

Dr. Miller comes to Ailux with an impressive background, accumulating over 25 years in both academic and industrial drug research and development. Prior to joining Ailux, he served as the Senior Vice President and Global Head of Translational Science at Johnson & Johnson Innovative Medicine, where he led a team of around 150 scientists and clinicians. Dr. Miller's extensive experience in various therapeutic areas such as Immunodermatology, Rheumatology, Gastroenterology, and Respiratory Medicine will be invaluable as Ailux continues to expand its focus within these fields.

Alex Li, CEO of Ailux, expressed enthusiasm over Dr. Miller's appointment, emphasizing the importance of his leadership during this pivotal phase. He stated, “Dr. Miller’s extensive clinical and research experience aligns perfectly with Ailux’s mission to address unmet medical needs through innovative therapies.” This newfound leadership is expected to guide Ailux’s AI-native programs through clinical development and help in aligning research with patient needs to enhance the company’s global biopharma vision.

As CMO, Dr. Miller's primary responsibility will be to push forward the development of biologic therapies, ensuring they reach trial stages efficiently and effectively. The role includes setting up clinical and research sites in the U.S. to complement ongoing efforts in Shanghai and the U.K., thus fortifying Ailux’s position as a competitive player in the biotech arena.

Dr. Miller's reputation in the field is underscored by his previous accomplishments, including the clinical development of ICOTYDE (icotrokinra), the first IL-23R-targeting therapy approved by the U.S. FDA for psoriasis in March 2026. His other significant contributions include advancing the FcRn blocker nipocalimab to registrational Phase 3 trials, which has the potential to redefine standard care for multiple diseases driven by autoantibodies.

In his own words, Dr. Miller conveyed his excitement about joining Ailux, stating, “The opportunity to translate Ailux’s AI-enabled biologics into transformative therapies is immense. I am eager to help create breakthrough treatments that prioritize safety and efficacy for patients with immune-mediated conditions.” His commitment to merging deep scientific insights with patient needs embodies Ailux's approach to biopharmaceutical developments.

Alongside his industry roles, Dr. Miller serves as an Adjunct Professor in Dermatology at both Johns Hopkins University School of Medicine and the University of Pennsylvania. His distinguished academic career features over 100 peer-reviewed publications, numerous invited presentations, and research grants from several prestigious organizations. Furthermore, he has played a crucial role in scientific committees and boards, contributing to advancements in the field of dermatology and beyond.

Ailux, headquartered in Shanghai, is a subsidiary of XtalPi, which specializes in next-generation biologics with a focus on combining proprietary AI technologies to enhance drug discovery. Established as a standalone entity five years ago, Ailux continues to build upon its strong foundation, with a dedicated global team working to innovate and expand its pipeline.

The future for Ailux appears bright with Dr. Miller at the helm of its medical division. His appointment is not only a testament to the company's commitment to innovation but also a strategic maneuver positioning Ailux to lead in the ever-evolving landscape of biotechnology. As clinical trials draw closer, Ailux enthusiasts and stakeholders alike await the transformative therapies that are on the horizon.